Home

STEVEN A KRIEGSMAN

CIK 1197482 · Chief Executive Officer · last filed 2020-08-13

STEVEN A KRIEGSMAN is a Chief Executive Officer who has filed 77 SEC Form 4 insider transactions across 6 companies since 2007. Across all open-market trades the lifetime net is −$3.8M, making them a net seller over the disclosed history. 58 SEC filings were submitted jointly with Galena Biopharma, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

6

Total Filings

77

Lifetime Open-Market Net

-$3.81M

Filer Profile

Reported Address
2165 TECHNOLOGY DRIVE
SCHENECTADY, NY 12308
Related Filers
Galena Biopharma, Inc. — 58 joint filings, latest 2015-06-23
CYTRX CORP — 24 joint filings, latest 2020-08-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LadRx Corp (CYTXW) Delisted CEO 387,597 — — $50.9K 13 2017-12-19
SELLAS Life Sciences Group, Inc. (GALE) Delisted Director 8,500 — — -$2.93M 5 2015-06-23
SELLAS Life Sciences Group, Inc. (RXII) Delisted Director 17 — — -$931.0K 51 2011-09-29
LadRx Corp (CYTR) Delisted Chief Executive Officer — — — $0 3 2008-11-24
Ontrak, Inc. (HYTM) Delisted Director — — — $0 1 2008-07-18
BRADLEY PHARMACEUTICALS INC (BDY) Delisted Director 25,000 — — $0 1 2008-02-21

Recent Filings

77 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-08-13 — Mixed +1,835,821 $0
2019-12-17 — Grant (A) — $0
2017-12-19 LadRx Corp (CYTXW) Delisted Grant (A) +387,597 $678.3K EDGAR
2016-12-20 LadRx Corp (CYTXW) Delisted Grant (A) +2,325,581 $1000.0K EDGAR
2016-12-19 LadRx Corp (CYTXW) Delisted Grant (A) — $0 EDGAR
2015-12-17 LadRx Corp (CYTXW) Delisted Grant (A) — $0 EDGAR
2015-06-23 SELLAS Life Sciences Group, Inc. (GALE) Delisted Grant (A) — $0 EDGAR
2015-04-28 — Grant (A) — $0
2014-12-16 LadRx Corp (CYTXW) Delisted Grant (A) — $0 EDGAR
2014-01-22 SELLAS Life Sciences Group, Inc. (GALE) Delisted Mixed — -$2.49M EDGAR
Showing 1–10 of 77
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.